These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 35557542

  • 1. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zhao Z, Jin P, Zhang Y, Hu X, Tian C, Liu D.
    Front Cardiovasc Med; 2022; 9():826684. PubMed ID: 35557542
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK.
    Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112
    [Abstract] [Full Text] [Related]

  • 3. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M, Maisnam I, Pal R, Mukhopadhyay S.
    Eur Heart J; 2023 Oct 01; 44(37):3686-3696. PubMed ID: 37605637
    [Abstract] [Full Text] [Related]

  • 4. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP.
    JAMA Cardiol; 2021 Feb 01; 6(2):148-158. PubMed ID: 33031522
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
    Gong C, Shen SC, Zhang K, Zhou L, Shen JJ, Zhao JY, Ding SG, Ma LK, Gao H.
    Front Cardiovasc Med; 2022 Feb 01; 9():926979. PubMed ID: 36312269
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK, Singh R.
    Diabetes Metab Syndr; 2021 Feb 01; 15(1):351-359. PubMed ID: 33503584
    [Abstract] [Full Text] [Related]

  • 9. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
    Wei W, Liu J, Chen S, Xu X, Guo D, He Y, Huang Z, Wang B, Huang H, Li Q, Chen J, Chen H, Tan N, Liu Y.
    Front Endocrinol (Lausanne); 2022 Feb 01; 13():850836. PubMed ID: 35330914
    [Abstract] [Full Text] [Related]

  • 10. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, Rangaswami J.
    Cardiorenal Med; 2020 Feb 01; 10(1):1-10. PubMed ID: 31743918
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM.
    Cardiovasc Diabetol; 2022 Mar 23; 21(1):47. PubMed ID: 35321742
    [Abstract] [Full Text] [Related]

  • 14. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
    Li X, Wu H, Peng H, Jiang H.
    Front Endocrinol (Lausanne); 2022 Mar 23; 13():1078686. PubMed ID: 36589800
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.
    Circulation; 2020 Dec 08; 142(23):2205-2215. PubMed ID: 33026243
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.